Q-omics provides the consensus-scored KANSL3 profile across patient tissues and cancer cell-line models. KANSL3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KANSL3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, KANSL3 protein abundance shows 27,085 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where KANSL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANSL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANSL3 survival associations across molecular data types. KANSL3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANSL3 RNA expression–survival associations across cancer types. High KANSL3 expression shows unfavorable associations in ACC, LIHC, LGG, KICH and LUSC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KANSL3 RNA expression.
This table summarizes KANSL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KANSL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANSL3 shows lower tumor expression in THCA, LUAD and KICH and higher tumor expression in HNSC, LIHC and KIRP. The HNSC box plot shows higher KANSL3 RNA expression in tumor versus normal tissue (log2 FC = +0.692, t-test p < 0.001).
This table shows molecular features associated with KANSL3 in patient tissues and cancer cell lines. In patient samples, KANSL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KANSL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
